Member Profile

Lukas biomedical is dedicated to the development of autologous immune cell therapy for cancer patients and has completed technology transfer from Lymphotec Inc. to launch the first T-cell (LuLym-T)-based clinical trial in Taiwan. Lukas biomedical is also developing new cell culture techniques for dendritic cells (LuLym-DC®), NK cells (LuLym-NK®) and Neo-antigen T cells (neo-LuLym®) to enhance the efficacy of LuLym-T. Phase 3 clinical trials has proven the efficacy of LuLym-T and is able to prevent recurrence and increase overall survival. Lukas will soon conduct Phase II clinical trial in USA as orphan drug for HCC and aims to achieve the first NDA for T cells in the world.